TOR_TRYCR
ID TOR_TRYCR Reviewed; 287 AA.
AC Q5J7P3; A2TKE1; A2TKE2;
DT 21-SEP-2011, integrated into UniProtKB/Swiss-Prot.
DT 15-FEB-2005, sequence version 1.
DT 25-MAY-2022, entry version 33.
DE RecName: Full=Tetraspanning orphan receptor {ECO:0000250|UniProtKB:C4QM85};
DE AltName: Full=Complement C2 receptor inhibitor tetraspanning {ECO:0000250|UniProtKB:C4QM85};
DE AltName: Full=Complement C2 receptor inhibitor trispanning {ECO:0000303|PubMed:15611259};
DE AltName: Full=Complement inhibitory receptor {ECO:0000312|EMBL:AAS46602.1};
DE AltName: Full=Trispanning orphan receptor {ECO:0000303|PubMed:10366712};
DE Short=Tc-TOR {ECO:0000303|PubMed:10366712};
DE Flags: Fragment;
GN Name=TOR {ECO:0000303|PubMed:10366712};
GN Synonyms=CRIT {ECO:0000312|EMBL:AAS46602.1};
OS Trypanosoma cruzi.
OC Eukaryota; Discoba; Euglenozoa; Kinetoplastea; Metakinetoplastina;
OC Trypanosomatida; Trypanosomatidae; Trypanosoma; Schizotrypanum.
OX NCBI_TaxID=5693;
RN [1] {ECO:0000305}
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX PubMed=10366712; DOI=10.1016/s0167-4781(99)00051-2;
RA Inal J.M.;
RT "Schistosoma TOR (trispanning orphan receptor), a novel, antigenic surface
RT receptor of the blood-dwelling, Schistosoma parasite.";
RL Biochim. Biophys. Acta 1445:283-298(1999).
RN [2] {ECO:0000312|EMBL:AAS46602.1}
RP NUCLEOTIDE SEQUENCE [MRNA].
RX PubMed=15611259; DOI=10.4049/jimmunol.174.1.356;
RA Inal J.M., Hui K.M., Miot S., Lange S., Ramirez M.I., Schneider B.,
RA Krueger G., Schifferli J.A.;
RT "Complement C2 receptor inhibitor trispanning: a novel human complement
RT inhibitory receptor.";
RL J. Immunol. 174:356-366(2005).
RN [3] {ECO:0000305, ECO:0000312|EMBL:ABN05634.1}
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, DEVELOPMENTAL STAGE, AND
RP VARIANTS SER-160; ASP-192 AND ARG-196.
RC STRAIN=CL Brenner {ECO:0000312|EMBL:ABN05635.1},
RC Colombiana {ECO:0000312|EMBL:ABN05636.1}, and
RC DM28c {ECO:0000312|EMBL:ABN05634.1};
RX PubMed=18781865; DOI=10.1086/592167;
RA Cestari Idos S., Evans-Osses I., Freitas J.C., Inal J.M., Ramirez M.I.;
RT "Complement C2 receptor inhibitor trispanning confers an increased ability
RT to resist complement-mediated lysis in Trypanosoma cruzi.";
RL J. Infect. Dis. 198:1276-1283(2008).
RN [4] {ECO:0000305}
RP FUNCTION, AND SUBCELLULAR LOCATION.
RX PubMed=19783051; DOI=10.1016/j.molimm.2009.08.030;
RA Cestari Idos S., Krarup A., Sim R.B., Inal J.M., Ramirez M.I.;
RT "Role of early lectin pathway activation in the complement-mediated killing
RT of Trypanosoma cruzi.";
RL Mol. Immunol. 47:426-437(2009).
CC -!- FUNCTION: Cell surface receptor that binds to human complement C2a
CC protein. This results in inhibition of the classical and lectin
CC pathways of complement activation, probably due to interference with
CC binding of C2a to C4b and interference with cleavage by C1 or MASP2
CC such that C3 convertase cannot be formed. This infers resistance to
CC complement-mediated cell lysis, allowing parasite survival and
CC infection. {ECO:0000269|PubMed:18781865, ECO:0000269|PubMed:19783051}.
CC -!- SUBUNIT: Interacts (via N-terminal extracellular domain) with human
CC C2a. {ECO:0000250|UniProtKB:Q9BLM6}.
CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:19783051};
CC Multi-pass membrane protein {ECO:0000269|PubMed:19783051}. Note=Located
CC on the surface tegumental plasma membrane of metacyclic trypomastigote
CC so in contact with host blood plasma. {ECO:0000269|PubMed:19783051}.
CC -!- DEVELOPMENTAL STAGE: In Y strain, expression is seen in metacyclic
CC trypomastigote form and in stationary, but not logarithmic-phase
CC epimastigote forms. In Colombiana strain, expression is seen in
CC metacyclic trypomastigote form only. {ECO:0000269|PubMed:18781865}.
CC -!- MISCELLANEOUS: The C-sensitive epimastigote form of the Colombiana
CC strain is more susceptible to lysis than the Y strain at all human
CC serum concentrations. Potential vaccine candidate molecule.
CC {ECO:0000269|PubMed:18781865, ECO:0000303|PubMed:10366712}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; AY464185; AAS46602.1; -; mRNA.
DR EMBL; EF212029; ABN05634.1; -; Genomic_DNA.
DR EMBL; EF212030; ABN05635.1; -; Genomic_DNA.
DR EMBL; EF212031; ABN05636.1; -; Genomic_DNA.
DR AlphaFoldDB; Q5J7P3; -.
DR PRIDE; Q5J7P3; -.
DR GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
PE 2: Evidence at transcript level;
KW Cell membrane; Membrane; Receptor; Transmembrane; Transmembrane helix.
FT CHAIN <1..287
FT /note="Tetraspanning orphan receptor"
FT /id="PRO_0000412761"
FT TOPO_DOM <1..27
FT /note="Extracellular"
FT /evidence="ECO:0000255"
FT TRANSMEM 28..48
FT /note="Helical"
FT /evidence="ECO:0000255"
FT TOPO_DOM 49..55
FT /note="Cytoplasmic"
FT /evidence="ECO:0000255"
FT TRANSMEM 56..76
FT /note="Helical"
FT /evidence="ECO:0000255"
FT TOPO_DOM 77..91
FT /note="Extracellular"
FT /evidence="ECO:0000255"
FT TRANSMEM 92..114
FT /note="Helical"
FT /evidence="ECO:0000255"
FT TOPO_DOM 115..287
FT /note="Cytoplasmic"
FT /evidence="ECO:0000255"
FT REGION 165..190
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 165..182
FT /note="Polar residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT VARIANT 160
FT /note="G -> S (in strain: CL Brenner)"
FT /evidence="ECO:0000269|PubMed:18781865"
FT VARIANT 192
FT /note="N -> D (in strain: Colombiana)"
FT /evidence="ECO:0000269|PubMed:18781865"
FT VARIANT 196
FT /note="K -> R (in strain: Colombiana)"
FT /evidence="ECO:0000269|PubMed:18781865"
FT NON_TER 1
FT /evidence="ECO:0000305"
SQ SEQUENCE 287 AA; 31792 MW; 5E907BC112B745ED CRC64;
MSPSLVSDTQ KHERGSHGVK IKHFSPYIAV CVTTFSLAFC CFMVHGAITR QPTHLLPFFF
IQVFDLIICL IHILGFMSST SDIRLVIHTK TGPIYIKSTG LTFIILSISR MMLAFKAYCL
GMVWDCYKYL MLNRRGNLLD DWYSDQWGHL STFWSLLRTG RNRGNNSIGN SGSPNEPNTR
PRPDTITYDP ANDLPKYEDI LKIPANAYTP PPYYCSNTNG NVNTTTTDAV TTNTTITSAT
TVNATTTITT NANTNTSTTT SVISPLTTTN KDDTQINNAS SNAHSSC
